source
- AstraZeneca’s Tagrisso plus Orpathys improves survival in MET-mutated lung cancerA new combination therapy using AstraZeneca’s Tagrisso together with Hutchmed’s Orpathys has shown a survival benefit for patients with a specific form of non‑small cell lung cancer. The study focu…
- AstraZeneca halts Phase 3 lung cancer trial of bispecific antibody volrustomig after interim data miss survival goalAstraZeneca announced termination of the Phase 3 study of its experimental bispecific antibody volrustomig in non‑small cell lung cancer. An interim data review by trial monitors indicated the dru…